We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Spero Therapeutics

News List

Spero Therapeutics Announces Proposed Offering of Common Stock firstwordpharma
July 10, 2018
Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections
Spero Therapeutics Receives Grant from NIH americanpharmaceuticalreview
May 05, 2017
Spero Therapeutics announced it has received a grant from the National Institutes of Health (NIH) to conduct additional preclinical studies of SPR720, the company's novel oral bacterial gyrase inhibitor, for the treatment of tuberculosis (TB).